XOMA to Present at Credit Suisse Antibody Day 2015
May 04 2015 - 4:31PM
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and
development of therapeutic antibodies, announced today that Paul
Rubin, the Company's Senior Vice President, Research and
Development, and Chief Medical Officer, is scheduled to present at
the Credit Suisse Antibody Day on May 6, 2015 at 8:35 a.m. Eastern
time.
A live audio webcast of the presentation can be accessed in the
Investors and Media section of XOMA's website at
http://investors.xoma.com/events.cfm. An archived version of the
webcast will be available via replay for 30 days following the
presentation.
About XOMA Corporation
XOMA Corporation is a leader in the discovery and development of
therapeutic antibodies. The Company's innovative product candidates
are the result of its expertise in developing ground-breaking
monoclonal antibodies, including allosteric modulating antibodies,
which have created new opportunities to potentially treat a wide
range of human diseases. XOMA is developing its lead product
gevokizumab (IL-1 beta modulating antibody) with Servier through a
global Phase 3 program for Behçet's disease uveitis and
non-infectious uveitis. XOMA also has an ongoing Phase 3 study
of gevokizumab in pyoderma gangrenosum. Additionally, XOMA's
scientific research has produced the XMet platform, which consists
of three classes of Selective Insulin Receptor Modulators (SIRMs)
antibodies. XOMA 358, the lead antibody in the XMetD program, is an
allosteric modulating monoclonal antibody that reduces both the
binding of insulin to its receptor and down-regulates insulin
signaling and could have a major effect on the treatment of
abnormal metabolic states. XOMA 358 recently completed Phase 1
testing. For more information, visit www.xoma.com.
CONTACT: Company and investor contacts:
Ashleigh Barreto
510-204-7482
barreto@xoma.com
Juliane Snowden
The Oratorium Group, LLC
jsnowden@oratoriumgroup.com
Media contact:
Ryan Flinn
W2O Group
415-946-1059
rflinn@w2ogroup.com
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Apr 2024 to May 2024
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From May 2023 to May 2024